Depomed, Inc., a specialty pharmaceutical company, engages in the development, sale, and licensing of products for pain and other central nervous system conditions in the United States. It offers Gralise (gabapentin), an once-daily product for the management of postherpetic neuralgia; CAMBIA (diclofenac potassium for oral solution), a non-steroidal anti-inflammatory drug indicated for acute treatment of migraine attacks in adults; and Zipsor (diclofenac potassium) liquid filled capsule, a non-steroidal anti-inflammatory drug for the treatment of mild to moderate acute pain in adults. The company also provides NUCYNTA ER (tapentadol extended release tablet), a product for the management of pain severe enough to long term opioid treatment, including neuropathic pain associated with diabetic peripheral neuropathy (DPN) in adults; and NUCYNTA IR (tapentadol), a product for the management of moderate to severe acute pain in adults. In addition, it is involved in the clinical development of Cebranopadol for the treatment of chronic nociceptive and neuropathic pain. Depomed, Inc. has a collaboration and license agreement with Ironwood Pharmaceuticals, Inc.; and a license agreement with Janssen Pharmaceuticals, Inc. based on its proprietary Acuform gastroretentive drug delivery technology. The company sells its products to wholesalers and retail pharmacies. Depomed, Inc. was founded in 1995 and is headquartered in Newark, California.
Industry, Sector and Symbol
Industry Pharmaceutical preparations
Sub-IndustryPharmaceuticals
SectorMedical
Phone510-744-8000
Debt
Price-To-Earnings
Sales & Book Value
Annual SalesN/A
Profitability
Miscellaneous
Employees434
OptionableOptionable
Depomed (NASDAQ:DEPO) Frequently Asked Questions
What is Depomed's stock symbol?
Depomed trades on the NASDAQ under the ticker symbol "DEPO."
How were Depomed's earnings last quarter?
Depomed Inc (NASDAQ:DEPO) announced its quarterly earnings results on Wednesday, August, 8th. The specialty pharmaceutical company reported $0.19 earnings per share (EPS) for the quarter, topping the Thomson Reuters' consensus estimate of $0.16 by $0.03. The specialty pharmaceutical company had revenue of $63.27 million for the quarter, compared to the consensus estimate of $63.72 million. The company's quarterly revenue was down 37.0% compared to the same quarter last year. During the same quarter last year, the company posted $0.08 EPS. View Depomed's Earnings History.
What price target have analysts set for DEPO?
5 brokerages have issued 12-month price objectives for Depomed's stock. Their predictions range from $8.00 to $10.00. On average, they expect Depomed's stock price to reach $9.00 in the next year. This suggests a possible upside of 23.3% from the stock's current price. View Analyst Price Targets for Depomed.
What is the consensus analysts' recommendation for Depomed?
5 Wall Street analysts have issued "buy," "hold," and "sell" ratings for Depomed in the last year. There are currently 2 hold ratings and 3 buy ratings for the stock, resulting in a consensus recommendation of "Buy." View Analyst Ratings for Depomed.
Has Depomed been receiving favorable news coverage?
News articles about DEPO stock have been trending somewhat positive on Saturday, InfoTrie Sentiment reports. InfoTrie identifies negative and positive news coverage by reviewing more than six thousand blog and news sources. The firm ranks coverage of public companies on a scale of -5 to 5, with scores nearest to five being the most favorable. Depomed earned a news impact score of 1.7 on InfoTrie's scale. They also gave news articles about the specialty pharmaceutical company a news buzz of 1.0 out of 10, meaning that recent news coverage is extremely unlikely to have an effect on the stock's share price in the near term.
Who are some of Depomed's key competitors?
Some companies that are related to Depomed include Advanced Accelerator Application (AAAP), Aerpio Pharmaceuticals (ARPO), AgeX Therapeutics (AGE), American Oriental Bioengineering (AOBI), Anthera Pharmaceuticals (ANTH), Aralez Pharmaceuticals (ARLZ), Argos Therapeutics (ARGS), ARMO Biosciences (ARMO), Biostar Pharmaceuticals (BSPM), Bohai Pharmaceuticals Group (BOPH), Cardiome Pharma (CRME), Concordia International (CXRXD), Concordia International (CXRX), Egalet (EGLT) and Eleven Biotherapeutics (EBIO).
Who are Depomed's key executives?
Depomed's management team includes the folowing people:
- Mr. Arthur Joseph Higgins, CEO, Pres & Director (Age 62)
- Mr. August J. Moretti, CFO & Sr. VP (Age 67)
- Mr. Sean P. McKercher, Sr. VP of Operations & Bus. (Age 61)
- Dr. Stan Bukofzer, Sr. VP and Chief Medical & Scientific Officer (Age 62)
- Mr. John B. Thomas, Sr. VP of IR & Corp. Communications (Age 54)
How do I buy shares of Depomed?
Shares of DEPO can be purchased through any online brokerage account. Popular online brokerages with access to the U.S. stock market include Vanguard Brokerage Services, TD Ameritrade, E*TRADE, Scottrade, Fidelity and Charles Schwab.
What is Depomed's stock price today?
One share of DEPO stock can currently be purchased for approximately $7.30.
What is Depomed's official website?
How can I contact Depomed?
Depomed's mailing address is 7999 GATEWAY BLVD. SUITE 300, NEWARK CA, 94560. The specialty pharmaceutical company can be reached via phone at 510-744-8000 or via email at [email protected]
MarketBeat Community Rating for Depomed (NASDAQ DEPO)
MarketBeat's community ratings are surveys of what our community members think about Depomed and other stocks. Vote "Outperform" if you believe DEPO will outperform the S&P 500 over the long term. Vote "Underperform" if you believe DEPO will underperform the S&P 500 over the long term. You may vote once every thirty days.
